Key result
The optimal antithrombotic therapy regimen and duration in peripheral artery disease remains unclear due to limited and conflicting data.
This article reviews current data on antithrombotic therapy in peripheral artery disease to address uncertainties regarding optimal regimen and duration.
Answers are grounded in this paper and cite their sources.
Uncertainty warrants individualized antithrombotic decisions in PAD; leaves open optimal regimen and duration for dedicated RCTs.
Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.
No takes yet. Share an insight, caveat, or question.
Foley et al. (2016) conducted a review in Peripheral artery disease. Antithrombotic therapy was evaluated. The optimal antithrombotic therapy regimen and duration in peripheral artery disease remains unclear due to limited and conflicting data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: